An interventional study of Multicomponent pain self-management programme in Hemophilic Arthropathy, Chronic Pain and Hemophilia A, sponsored by Investigación en Hemofilia y Fisioterapia. Not yet recruiting at 1 site in Spain. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Investigación en Hemofilia y Fisioterapia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 174 studies in Chronic Pain with a site in Spain — 34 open to participants now, 40 under way, 1 of them phase 3. Chronic Pain · Spain.
Among the 174 studies in Chronic Pain with a site in Spain, this one is the 65th largest by planned enrollment of the 141 interventional ones that give a count, is the only one that started in 2027, is one of 126 with no phase, reaches primary completion later than 31 of the 39 other live ones, and was the 171st registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →34 of the 174 studies in Chronic Pain with a site in Spain are open now. Recruiting first, the newest first:
Biobizkaia Health Research Institute · Sites in Spain
Ages 35–75
Bernardino Clavo, MD, PhD · Sites in Spain
Ages 18+
Fundación Universidad Católica de Valencia San Vicente Mártir · Sites in Spain
Ages 18–70
University of Salamanca · Sites in Spain
Ages 65+
Investigación en Hemofilia y Fisioterapia · Sites in Spain
Ages 18+ · Men only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
174 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 9 · Phase 4 3
First in 2003; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 66 across the 141 interventional studies, 268 across the 33 observational. Of the 113 that completed or were terminated, 17 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 174 have an industry lead sponsor. The 10 most frequent:
Investigación en Hemofilia y Fisioterapia is the lead sponsor of 57 studies on the registry; 6 are open to participants now.
Investigación en Hemofilia y Fisioterapia has 7 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
8 of the studies in Chronic Pain with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07693998University of ValenciaPain Neuroscience Education for Chronic Pain | 2026-12-31 |
| NCT07467408Consorci Sanitari de TerrassaTreatment of Mechanical Low Back Pain With High-Intensity Focused Ultrasound (HIFU) | 2026-12-31 |
| NCT07498569Universidad Miguel Hernandez de ElcheEffects of Percutaneous Electrical Stimulation in Patients With Chronic Supraspinatus Tendinopathy | 2027-06-01 |
| NCT07420387Investigación en Hemofilia y FisioterapiaEffectiveness of an Educational Program for Pain Management in Patients With Hemophilic Arthropathy | 2027-06-28 |
| NCT07313280University of MalagaCentral Sensitization Syndromes and Post-Traumatic Stress in Women: Psychological Profile and Intervention | 2027-07 |
Add all 8 to your calendar (.ics) → With an account.
Among the 174 studies in Chronic Pain with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background: Haemophilic arthropathy is associated with chronic pain, functional limitation and impaired quality of life. Pain interference may also be influenced by cognitive, emotional and behavioural factors. Evidence for structured multicomponent pain self-management programmes specifically tailored to adults with haemophilic arthropathy remains limited.
Objective: To evaluate the effectiveness of a structured multicomponent pain self-management programme, compared with usual care, in reducing pain interference in adults with haemophilia A or B, haemophilic arthropathy and chronic pain.
Methods: Approximately 70 adults will be individually randomised in a 1:1 ratio to a multicomponent pain self-management programme or usual care. The intervention will comprise three 60-minute face-to-face group sessions delivered over approximately 6-8 weeks. The programme will integrate pain education, emotional-regulation training and cognitive-behavioural self-management strategies. Assessments will be performed at baseline, immediately after the intervention and at 6 months. The primary outcome will be the between-group difference in change in Brief Pain Inventory-Interference score from baseline to 6 months.
This is a superiority, individually randomised, partially nested controlled trial with two parallel groups and a 1:1 allocation ratio. Participants allocated to the experimental arm will receive a structured multicomponent pain self-management programme delivered in three educational cohorts of approximately 11-12 participants. The control group will continue with usual care during the 6-month study period.
The intervention will comprise three face-to-face sessions of approximately 60 minutes delivered at 3-4-week intervals. It will integrate education on pain neurobiology and modulation, emotional-regulation training and cognitive-behavioural coping strategies. Content will be specifically adapted to haemophilic arthropathy, including education on distinguishing persistent pain from symptoms suggestive of acute haemarthrosis and a standardised safety pathway for suspected bleeding.
Participants in the control group will continue routine haematological follow-up, prescribed haemostatic and analgesic treatment and their usual physical activity, exercise or physiotherapy. Following completion of the 6-month assessment, control participants will be offered the same multicomponent programme.
Outcomes will be assessed at baseline, immediately after the third intervention session and at 6 months. The primary outcome will be pain interference assessed using the Brief Pain Inventory-Short Form. Secondary outcomes will include pain intensity, kinesiophobia, pain catastrophising, anxiety, depressive symptoms, illness perception, health-related quality of life and physical activity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive three face-to-face group sessions of approximately 60 minutes delivered at 3-4-week intervals over approximately 6-8 weeks. The programme integrates pain education, emotional-regulation training and cognitive-behavioural self-management strategies specifically adapted to adults with haemophilic arthropathy.
Other: Multicomponent pain self-management programme
Participants will continue their usual care, including routine haematological follow-up, prescribed haemostatic and analgesic treatment and their usual physical activity, exercise or physiotherapy routines. They will not receive the structured pain self-management programme or its educational materials before completion of the 6-month follow-up. After the final 6-month assessment, they will be offered the same multicomponent programme as the experimental group.
The intervention comprises three structured face-to-face group sessions. Content includes pain neurobiology and modulation; distinctions between nociception, pain and tissue damage; biopsychosocial and fear-avoidance models; emotional regulation; diaphragmatic breathing; mindfulness; acceptance and resilience; physical activity; identification of maladaptive beliefs and cognitive distortions; cognitive restructuring; self-instruction; guided imagery; physiological de-arousal; and development of an individual self-management plan. Participants will also receive digital educational materials and between-session home assignments. A standardised safety pathway for suspected acute haemarthrosis will be included.
Change in pain interference from baseline to 6 months
Pain interference will be assessed using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-Interference score is calculated as the mean of seven items scored from 0 to 10, with higher scores indicating greater interference of pain with daily life. The primary outcome is the between-group difference in mean change from baseline to the 6-month follow-up.
Time frame: Baseline and 6 months
Change in pain interference immediately after the intervention
BPI-Interference score, calculated as the mean of seven items scored from 0 to 10; higher scores indicate greater pain interference.
Time frame: Baseline and immediately after Session 3
Change in pain intensity
Pain intensity will be assessed using the BPI-Severity subscale of the Brief Pain Inventory-Short Form, calculated from its four pain-intensity items. Higher scores indicate greater pain intensity.
Time frame: Baseline, immediately after Session 3, and 6 months
Change in kinesiophobia
Kinesiophobia will be assessed using the Spanish version of the Tampa Scale for Kinesiophobia-11SV. Higher scores indicate greater fear of movement.
Time frame: Baseline, immediately after Session 3, and 6 months
Change in pain catastrophising
Pain catastrophising will be assessed using the Spanish version of the Pain Catastrophizing Scale. Higher scores indicate greater pain catastrophising.
Time frame: Baseline, immediately after Session 3, and 6 months
Change in health-related quality of life
Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36). The eight SF-36 domains and the physical and mental component summary scores will be analysed. Higher scores indicate better health-related quality of life.
Time frame: Baseline, immediately after Session 3, and 6 months
Change in depressive symptoms
Depressive symptoms will be assessed using the Beck Depression Inventory-II (BDI-II), a 21-item self-report questionnaire. Higher scores indicate greater depressive symptom severity.
Time frame: Baseline, immediately after Session 3, and 6 months
Change in anxiety
Anxiety will be assessed using the State-Trait Anxiety Inventory (STAI), comprising 20-item state-anxiety and 20-item trait-anxiety subscales. Higher scores indicate greater anxiety.
Time frame: Baseline, immediately after Session 3, and 6 months
Change in illness perception
Illness perception will be assessed using the Brief Illness Perception Questionnaire (BIPQ), which assesses cognitive and emotional representations of illness and perceived illness threat.
Time frame: Baseline, immediately after Session 3, and 6 months
Change in physical activity
Physical activity will be assessed using the International Physical Activity Questionnaire-Short Form (IPAQ-SF), with a 7-day recall period. Vigorous and moderate physical activity, walking and sedentary behaviour will be recorded according to the instrument scoring protocol.
Time frame: Baseline, immediately after Session 3, and 6 months
Bleeding episodes and adverse events
Bleeding episodes, clinically relevant increases in pain and adverse events reported by participants will be recorded throughout follow-up.
Time frame: From baseline to the 6-month follow-up
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2027; primary completion for Dec 2027, 9 months later.
Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 9 months is below that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Investigación en Hemofilia y Fisioterapia